secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0001628280-22-007701
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma reports Q4/FY2021 net loss $250.2M; cash $898M; two INDs cleared
--------------------------------------------------------------------------------

- Net loss $250.2M in FY2021 vs $204.5M in 2020; non-GAAP net loss $147.9M.
- R&D expense $138.7M in FY2021, down from $182.2M; G&A expense $89.1M vs $46.9M.
- Cash, cash equivalents and marketable securities $898M as of Dec 31, 2021.
- FDA cleared INDs for LYL797 (CAR T targeting ROR1) and LYL132 (TCR targeting NY-ESO-1); initial data from LYL797 trial expected in 2023.
- LYL845 TIL therapy IND on track for H2 2022; LYL331 IND (GSK collaboration) delayed to late 2022/early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022007701/0001628280-22-007701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022007701/lyel-20220329.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-007701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer